Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-10-18
Target enrollment:
Participant gender:
Summary
The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been
well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone,
azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed
advanced stage ENKTL
, non-upper aerodigestive tract NK/T- cell lymphoma（NUAT- NKTCL）and relapsed refractory NK/T
cell lymphoma.